About Pharmatest

Pharmatest is a preclinical contract research organization (CRO) providing specialized _in vitro_ and _in vivo_ services for oncology and skeletal disease drug development. They offer validated models, including bone metastasis and osteoporosis assays, to improve the clinical predictivity of novel therapeutics.

<problem> Developing novel therapeutics for oncology and skeletal diseases requires robust preclinical models that accurately predict clinical outcomes. The high failure rate in clinical trials suggests a gap in the predictivity of current preclinical testing methodologies. </problem> <solution> Pharmatest provides comprehensive preclinical contract research organization (CRO) services, specializing in oncology and skeletal disease models. The company offers a range of _in vitro_, _in vivo_, and _ex vivo_ assays designed to enhance the clinical predictivity of drug candidates. By focusing on complex disease microenvironments, such as bone metastases, and leveraging expertise in radiopharmaceutical testing, Pharmatest aims to accelerate drug development timelines and improve the success rate of new therapies entering clinical trials. Their validated models and specialized services support clients from early-stage research through to regulatory submissions. </solution> <features> - Full-service preclinical CRO with expertise in oncology and skeletal disease models. - Specialized focus on bone metastasis models, replicating the tumor microenvironment for enhanced clinical relevance. - Extensive portfolio of _in vitro_ assays for cell viability, apoptosis, cytotoxicity, migration, and immune cell killing. - Diverse _in vivo_ efficacy models, including xenografts (subcutaneous, orthotopic, metastatic) and syngeneic models in immunocompetent mice. - Expertise in skeletal disease models, encompassing osteoporosis (OVX, ORX, GIO) and osteoarthritis (MIA, MMT+MCLT, ACLT, pMMx models in rats and rabbits). - Specialized services for targeted radionuclide therapy, including _in vitro_ and _in vivo_ studies with alpha and beta emitters (e.g., Ra-223, Th-227, Lu-177). - Comprehensive bone analysis services utilizing techniques such as micro-computed tomography (µCT), pQCT, DXA, and histomorphometry. - Biomarker testing services for preclinical and clinical samples, including bone formation and resorption markers, as well as assays in oncology, endocrinology, and immunology. - Capability to perform studies according to FDA and EMA guidelines, supporting regulatory submissions. </features> <target_audience> Pharmaceutical and biotechnology companies engaged in oncology and skeletal disease drug discovery and development. </target_audience>

What does Pharmatest do?

Where is Pharmatest located?

Pharmatest is based in Turku, Finland.

When was Pharmatest founded?

Pharmatest was founded in 1998.

Location

Turku, Finland

Founded

1998

Employees

19 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Pharmatest

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

pharmatest.com 2K+

Crunchbase

Founded 1998 – Turku, Finland

Funding

No funding information available.

Team (15+)

No team information available.

Company Description

Problem

Developing novel therapeutics for oncology and skeletal diseases requires robust preclinical models that accurately predict clinical outcomes. The high failure rate in clinical trials suggests a gap in the predictivity of current preclinical testing methodologies.

Solution

Pharmatest provides comprehensive preclinical contract research organization (CRO) services, specializing in oncology and skeletal disease models. The company offers a range of _in vitro_, _in vivo_, and _ex vivo_ assays designed to enhance the clinical predictivity of drug candidates. By focusing on complex disease microenvironments, such as bone metastases, and leveraging expertise in radiopharmaceutical testing, Pharmatest aims to accelerate drug development timelines and improve the success rate of new therapies entering clinical trials. Their validated models and specialized services support clients from early-stage research through to regulatory submissions.

Features

Full-service preclinical CRO with expertise in oncology and skeletal disease models.

Specialized focus on bone metastasis models, replicating the tumor microenvironment for enhanced clinical relevance.

Extensive portfolio of _in vitro_ assays for cell viability, apoptosis, cytotoxicity, migration, and immune cell killing.

Diverse _in vivo_ efficacy models, including xenografts (subcutaneous, orthotopic, metastatic) and syngeneic models in immunocompetent mice.

Expertise in skeletal disease models, encompassing osteoporosis (OVX, ORX, GIO) and osteoarthritis (MIA, MMT+MCLT, ACLT, pMMx models in rats and rabbits).

Specialized services for targeted radionuclide therapy, including _in vitro_ and _in vivo_ studies with alpha and beta emitters (e.g., Ra-223, Th-227, Lu-177).

Comprehensive bone analysis services utilizing techniques such as micro-computed tomography (µCT), pQCT, DXA, and histomorphometry.

Biomarker testing services for preclinical and clinical samples, including bone formation and resorption markers, as well as assays in oncology, endocrinology, and immunology.

Capability to perform studies according to FDA and EMA guidelines, supporting regulatory submissions.

Target Audience

Pharmaceutical and biotechnology companies engaged in oncology and skeletal disease drug discovery and development.